Dermata to launch Tome Foundational Treatment on Aug 25, 2026; cash $4.4M

Dermata Therapeutics, Inc.

Tome Foundational Treatment launch expected Aug 25, 2026; manufacturing and packaging complete.
Cash and equivalents $4.4M at June 30, 2026 vs $7.5M at Dec 31, 2025; sufficient into Q4 2026.
Q2 2026 R&D expenses $0.2M (down from $0.6M); SG&A $2.8M (up from $1.2M) on legal, marketing, compensation.
Second DTC product, an OTC acne treatment, planned after Foundational Treatment launch.
Company attended Be+Well Beauty and Wellness Show in June; began Tome social media campaign.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.